AstraZeneca presented trial data at the European Society of Cardiology Congress.
1 report, 1 independent
Updated Sep 2
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
AstraZeneca presented trial data at the European Society of Cardiology Congress.
Who's involved
What this event is mainly aboutKeep exploring
The entities involved
-
AstraZeneca
British-Swedish pharmaceutical company
-
European Society of Cardiology
non-profit knowledge-based professional association
Related events
- Tenax Therapeutics presented findings and announced results at the European Society of Cardiology Congress 2026.
- Trial results regarding HeartFlow Inc. were presented at the ESC Congress, focusing on how AI technology supports the guidelines of the American College of Cardiology.
- Research addressing limitations in ESC guidelines was presented, involving Aalborg University and Aamir Mahmood.
- AstraZeneca discontinued the eVOLVE-Lung02 trial on August 18, 2026.
- The European Society of Cardiology Congress is currently being held in Munich, with trials targeting enrollment from both countries.
Coverage
Newest first; wire copies grouped- BenzingaAstraZeneca's Latest Drug Offers Hope For Millions Battling Hard-To-Control Blood Pressure On Saturday, AstraZeneca Plc (NASDAQ:AZN) released full results from the BaxHTN Phase 3 trial evaluating bax